Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Allo-Ocimene SCHEMBL58047 | 1.00 | ALDH1A1 (0.39) | ALDH1A1ALOX15RECQLHSD17B10TDP1 | |
| Allo-Ocimene SCHEMBL1305738 | 1.00 | ALDH1A1 (0.39) | ALDH1A1ALOX15RECQLHSD17B10TDP1 | |
| Allo-Ocimene SCHEMBL58046 | 1.00 | ALDH1A1 (0.39) | ALDH1A1ALOX15RECQLHSD17B10TDP1 | |
| Allo-Ocimene SCHEMBL1810809 | 1.00 | ALDH1A1 (0.39) | ALDH1A1ALOX15RECQLHSD17B10TDP1 | |
| Allo-Ocimene SCHEMBL10749071 | 1.00 | ALDH1A1 (0.39) | ALDH1A1ALOX15RECQLHSD17B10TDP1 | |
| Allo-Ocimene SCHEMBL5145283 | 1.00 | ALDH1A1 (0.39) | ALDH1A1ALOX15RECQLHSD17B10TDP1 | |
| SCHEMBL30336957 | 0.94 | ALDH1A1 (0.46) | ALDH1A1ALOX15RECQLHSD17B10TDP1 | |
| Allo-Ocimene SCHEMBL712009 | 0.92 | TSHR (0.34) | ALDH1A1ALOX15RECQLHSD17B10TDP1 | |
| Allo-Ocimene SCHEMBL7017740 | 0.89 | ALDH1A1 (0.38) | ALDH1A1ALOX15RECQLHSD17B10TDP1 | |
| Allo-Ocimene SCHEMBL15327055 | 0.83 | NR1I2 (0.33) | ALDH1A1ALOX15RECQLHSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2493461-B9 | POLYMERIC MONOTERPENES FOR TREATING IMPAIRED NEUROLOGICAL FUNCTION | REGENERA PHARMA LTD (IL) | 2016-05-18 | — | — | EP | disclosed |
| EP-2493461-B1 | POLYMERIC MONOTERPENES FOR TREATING IMPAIRED NEUROLOGICAL FUNCTION | REGENERA PHARMA LTD (IL) | 2016-01-06 | — | — | EP | disclosed |
| US-20150079021-A1 | THERAPEUTIC USES OF OLIGOMERIC AND POLYMERIC MONOTERPENES | REGENERA PHARMA LTD. | 2015-03-19 | — | — | US | disclosed |
| EP-2493461-A1 | THERAPEUTIC USES OF OLIGOMERIC AND POLYMERIC MONOTERPENES | Regenera Pharma Ltd. (IL) | 2012-09-05 | — | — | EP | disclosed |
| US-20120213727-A1 | THERAPEUTIC USES OF OLIGOMERIC AND POLYMERIC MONOTERPENES | REGENERA PHARMA LTD. (IL) | 2012-08-23 | — | — | US | disclosed |
| WO-2011051945-A1 | THERAPEUTIC USES OF OLIGOMERIC AND POLYMERIC MONOTERPENES | REGENERA PHARMA LTD. (IL) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120213727-A1 | THERAPEUTIC USES OF OLIGOMERIC AND POLYMERIC MONOTERPENES | APP, SQLE, PTAR1 | ALDH1A1 791/4885ALOX15 28/4885RECQL 2733/4885 |
| US-20150079021-A1 | THERAPEUTIC USES OF OLIGOMERIC AND POLYMERIC MONOTERPENES | HSD3B1, HSD3B2, CYP17A1 | ALDH1A1 740/4885ALOX15 104/4885RECQL 1888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.